Rh-Endostatin抗血管生成及与其他疗法联合抗肿瘤的研究进展

Progress about Rh-Endostatin combined with other treatments to treat malignancy

重组人血管内皮抑素(rh-Endostatin,rh-ES)是经国家食品药品监督管理局(SFDA)批准上市的我国自主研发的一种新型靶向抗血管生成药物,能选择性地抑制微血管内皮的增殖、迁徙、粘附和存活。rh-ES的临床应用及其机理虽已得到深入研究,但其最佳使用方案仍在持续探索中。本文试就rh-ES抗血管生成及与其他疗法联合抗肿瘤的研究进展做一综述。

Rh-Endostatin,which is an independent-developed new anti-angiogenes drug and approved by the SFDA,can restrain proliferation,migration,adhesion and survival of microvascular endothelium selectively.Even though the clinical application and mechanism of rh-ES has been subjected to intensive studies,the optimal regimen is still under explored.Given the point of view mentioned above,this paper tries to summarize the research developments on the antiangiogensis functions of rh-ES and the treatments which combined rh-ES with other anti-tumor therapeutics.